Leerink Partners Maintains Outperform on Spyre Therapeutics, Raises Price Target to $106

Benzinga Newsdesk www.benzinga.com Positive 92.1%

Neg 0% Neu 0% Pos 92.1%

Leerink Partners analyst Thomas Smith maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and raises the price target from $49 to $106.